Syncona shifting funds into cash – Syncona is changing the way it invests the portion of its portfolio that is not committed to biotech investments.
It says: “Over the last two years, Syncona has evolved the investment parameters of its strategic capital pool to focus on liquidity and capital preservation in order to support Syncona’s strategy and key goal of founding, building and funding global leaders in life science. To support this strategy, we will be simplifying the management of Syncona’s capital pool. Accordingly, over the next three to six months, Syncona will be significantly reducing its fund investments and further increasing its weighting to cash, cash equivalents and fixed income products with higher liquidity and lower volatility.”
Martin Murphy, CEO, Syncona Investment Management Limited, said: “This is a natural next step for the management of our capital pool. Our life science portfolio has generated significant value to date, with the offer for Nightstar demonstrating our ability to deliver strong returns. Successful life science companies scale rapidly, and our existing portfolio is now at the stage where our strategic capital pool ideally positions Syncona to capitalise on the commercial opportunities ahead of us.
I would like to thank our Head of Fund Investments, Arabella Cecil, for her great contribution to Syncona, successfully managing the fund investments as part of our strategic pool of capital to enable us to fund our vision to create global leaders in life science.”
SYNC : Syncona shifting funds into cash